Cancer of unknown primary site
dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Pentheroudakis, George | en |
dc.date.accessioned | 2018-06-22T09:54:21Z | |
dc.date.available | 2018-06-22T09:54:21Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42317 | |
dc.description.abstract | Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5 of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. Diagnostic approaches to identify the primary site include detailed histopathological examination with specific immunohistochemistry and radiological assessment. Gene-profiling microarray diagnosis has high sensitivity, but further prospective study is necessary to establish whether patients' outcomes are improved by its clinical use. Metastatic adenocarcinoma is the most common CUP histopathology (80). CUP patients are divided into subsets of favourable (20) and unfavourable (80) prognosis. Favourable subsets are mostly given locoregional treatment or systemic platinum-based chemotherapy. Responses and survival are similar to those of patients with relevant known primary tumours. Patients in unfavourable subsets are treated with empirical chemotherapy based on combination regimens of platinum or taxane, but responses and survival are generally poor. © 2012 Elsevier Ltd. | en |
dc.language.iso | eng | en |
dc.source | The Lancet | en |
dc.subject | Female | en |
dc.subject | Male | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Cancer chemotherapy | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Aged | en |
dc.subject | Humans | en |
dc.subject | Breast cancer | en |
dc.subject | Middle aged | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Computer assisted tomography | en |
dc.subject | Disease progression | en |
dc.subject | Neoplasm staging | en |
dc.subject | Paclitaxel | en |
dc.subject | Priority journal | en |
dc.subject | Magnetic resonance imaging | en |
dc.subject | Taxane derivative | en |
dc.subject | Platinum | en |
dc.subject | Prognosis | en |
dc.subject | Survival analysis | en |
dc.subject | Lung cancer | en |
dc.subject | Cancer diagnosis | en |
dc.subject | Cancer prognosis | en |
dc.subject | Cancer radiotherapy | en |
dc.subject | Bone metastasis | en |
dc.subject | Trastuzumab | en |
dc.subject | Carcinoma | en |
dc.subject | Disease course | en |
dc.subject | Clinical feature | en |
dc.subject | Conference paper | en |
dc.subject | Immunohistochemistry | en |
dc.subject | Protein p53 | en |
dc.subject | Lymphatic metastasis | en |
dc.subject | Neoplasm invasiveness | en |
dc.subject | Axillary lymph node | en |
dc.subject | Histopathology | en |
dc.subject | Lymph node dissection | en |
dc.subject | Mastectomy | en |
dc.subject | Rectum cancer | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Stomach cancer | en |
dc.subject | Risk assessment | en |
dc.subject | Prostate cancer | en |
dc.subject | Nuclear magnetic resonance imaging | en |
dc.subject | Treatment response | en |
dc.subject | Needle biopsy | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Squamous cell carcinoma | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Unknown primary | en |
dc.subject | Visceral metastasis | en |
dc.subject | Pancreas cancer | en |
dc.subject | Undifferentiated carcinoma | en |
dc.subject | Combined modality therapy | en |
dc.subject | Endoscopy | en |
dc.subject | Pathophysiology | en |
dc.subject | Cytokeratin | en |
dc.subject | Neuroendocrine tumor | en |
dc.subject | Cervical lymph node | en |
dc.subject | Early diagnosis | en |
dc.subject | Microarray analysis | en |
dc.subject | Gene expression profiling | en |
dc.subject | Carcinomatous peritonitis | en |
dc.subject | Genetic analysis | en |
dc.subject | Tomography | en |
dc.subject | Colon adenocarcinoma | en |
dc.subject | Biopsy | en |
dc.subject | Lymph nodes | en |
dc.subject | Needle | en |
dc.subject | X-ray computed | en |
dc.subject | Molecular diagnosis | en |
dc.subject | Ras protein | en |
dc.subject | Liver cancer | en |
dc.subject | Papillary carcinoma | en |
dc.subject | Endocrine tumor | en |
dc.subject | Diagnostic imaging | en |
dc.subject | Disease classification | en |
dc.subject | Genital tract cancer | en |
dc.subject | Lymph node biopsy | en |
dc.subject | Oncogene myc | en |
dc.subject | Radiodiagnosis | en |
dc.title | Cancer of unknown primary site | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/S0140-6736(11)61178-1 | |
dc.description.volume | 379 | |
dc.description.issue | 9824 | |
dc.description.startingpage | 1428 | |
dc.description.endingpage | 1435 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |